Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Shuichi Kaneko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3137-8183; OpenAlex author ID A5069065380. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
13
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 10

  1. Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer. Co-author DOI 10.1002/1878-0261.13796↗
  2. Efficacy of a novel self-expandable metal stent with dumbbell-shaped flare ends for distal biliary obstruction due to unresectable pancreatic cancer. Last author DOI 10.1038/s41598-022-25186-2↗
  3. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer … Co-author DOI 10.1136/jitc-2020-001367↗
  4. Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. Last author DOI 10.1080/09553002.2019.1558297↗
  5. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Last author DOI 10.1111/cas.13944↗
  6. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells. Last author DOI 10.1111/cas.13971↗
  7. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Last author DOI 10.1093/jjco/hyy132↗
  8. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13396↗
  9. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Last author DOI 10.1111/cas.12663↗
  10. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Last author DOI 10.1007/s00262-014-1529-8↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshio Sakai · 8 shared papers, 2015–2025 · strength 0.81
  2. Taro Yamashita · 5 shared papers, 2019–2025 · strength 0.62
  3. Alessandro Nasti · 5 shared papers, 2019–2025 · strength 0.57
  4. Akihiro Seki · 3 shared papers, 2019–2025 · strength 0.42
  5. Tuyen Thuy Bich Ho · 3 shared papers, 2019–2025 · strength 0.42
  6. Takuya Komura · 5 shared papers, 2015–2020 · strength 0.36
  7. Masaki Miyazawa · 3 shared papers, 2017–2022 · strength 0.27
  8. Takeshi Terashima · 4 shared papers, 2014–2019 · strength 0.25
  9. Tetsuo Ohta · 2 shared papers, 2015–2017 · strength 0.11
  10. Haruo Fujinaga · 1 shared paper, 2019 · strength 0.08
  11. Akito Sakai · 1 shared paper, 2018 · strength 0.07
  12. Shigeyuki Matsui · 1 shared paper, 2019 · strength 0.07
  13. Koushiro Ohtsubo · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.